Second Sight Medical Products Stock Forecast, Price & News

-0.04 (-1.04 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.20 million shs
Average Volume4.32 million shs
Market Capitalization$144.82 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive EYES News and Ratings via Email

Sign-up to receive the latest news and ratings for Second Sight Medical Products and its competitors with MarketBeat's FREE daily newsletter.

Second Sight Medical Products logo

About Second Sight Medical Products

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.21 out of 5 stars

Medical Sector

1310th out of 2,220 stocks

Electromedical Equipment Industry

35th out of 64 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Second Sight Medical Products (NASDAQ:EYES) Frequently Asked Questions

What stocks does MarketBeat like better than Second Sight Medical Products?

Wall Street analysts have given Second Sight Medical Products a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Second Sight Medical Products wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Second Sight Medical Products?

Second Sight Medical Products saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 3,240,000 shares, an increase of 24.6% from the June 30th total of 2,600,000 shares. Based on an average trading volume of 5,980,000 shares, the short-interest ratio is presently 0.5 days.
View Second Sight Medical Products' Short Interest

When is Second Sight Medical Products' next earnings date?

Second Sight Medical Products is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Second Sight Medical Products

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products, Inc. (NASDAQ:EYES) announced its quarterly earnings data on Monday, June, 29th. The medical device company reported ($0.57) EPS for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.16.
View Second Sight Medical Products' earnings history

How has Second Sight Medical Products' stock been impacted by Coronavirus (COVID-19)?

Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EYES stock has increased by 8.2% and is now trading at $3.82.
View which stocks have been most impacted by COVID-19

Who are Second Sight Medical Products' key executives?

Second Sight Medical Products' management team includes the following people:
  • Mr. Scott Dunbar, Acting Chief Exec. Officer (Age 64, Pay $255.3k)
  • Mr. Edward Jonathon Sedo, Acting Chief Accounting Officer & Principal Financial Officer (Age 65, Pay $151.08k)
  • Mr. Edward David Randolph, VP of Operations (Age 63, Pay $167.5k)
  • Dr. Jessy Dana Dorn Ph.D., VP of Clinical & Scientific Affairs (Age 45, Pay $233.99k)
  • Gunnar Bjorg, Founder
  • Mr. Stephen D. Okland Jr., Chief Strategy & Bus. Devel. Officer (Age 57)
  • Ms. Lisa M. Wilson, Founder & Pres of In-Site Communications and Investor Relations for Second Sight (Age 56)

What is Will McGuire's approval rating as Second Sight Medical Products' CEO?

5 employees have rated Second Sight Medical Products CEO Will McGuire on Will McGuire has an approval rating of 57% among Second Sight Medical Products' employees. This puts Will McGuire in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Second Sight Medical Products' key competitors?

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), VBI Vaccines (VBIV), Shopify (SHOP), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), (CGC), Ekso Bionics (EKSO) and OPKO Health (OPK).

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an initial public offering on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.

What is Second Sight Medical Products' stock symbol?

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Who are Second Sight Medical Products' major shareholders?

Second Sight Medical Products' stock is owned by many different institutional and retail investors. Top institutional shareholders include Cutler Group LP (0.00%) and GWM Advisors LLC (0.03%).
View institutional ownership trends for Second Sight Medical Products

Which institutional investors are buying Second Sight Medical Products stock?

EYES stock was bought by a variety of institutional investors in the last quarter, including Cutler Group LP, and GWM Advisors LLC.
View insider buying and selling activity for Second Sight Medical Products
or or view top insider-buying stocks.

How do I buy shares of Second Sight Medical Products?

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Second Sight Medical Products' stock price today?

One share of EYES stock can currently be purchased for approximately $3.82.

How much money does Second Sight Medical Products make?

Second Sight Medical Products has a market capitalization of $144.82 million and generates $3.38 million in revenue each year.

How many employees does Second Sight Medical Products have?

Second Sight Medical Products employs 11 workers across the globe.

What is Second Sight Medical Products' official website?

The official website for Second Sight Medical Products is

Where are Second Sight Medical Products' headquarters?

Second Sight Medical Products is headquartered at 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342.

How can I contact Second Sight Medical Products?

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.